Pre-therapeutic PSMA PET Imaging Biomarkers Demonstrate Prognostic Value in Patients Undergoing [ 177 Lu]Lu-PSMA Therapy: A Systematic Review and Meta-analysis.
Kaylee Molin, Suning Li, Nathaniel Barry et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the prognostic value of pre-therapeutic PSMA PET imaging biomarkers in 2993 patients undergoing [177 Lu]Lu-PSMA therapy for metastatic castration-resistant prostate cancer. The study found that each unit increase in SUV mean was associated with a reduced risk of death (HR = 0.88) and improved PSA progression-free survival (HR = 0.870).
Key findings
- Each unit increase in SUV mean reduced the risk of death (HR = 0.88; P < .001).
- Higher SUV mean was linked to improved odds of PSA50 response (odds ratio = 2.12; P = .010).
- Higher PSMA-TV was associated with poorer overall survival.
- PSMA-TLQ showed stronger associations with survival compared to PSMA-TLU.
Why it matters
Understanding the prognostic value of PSMA PET biomarkers can enhance patient selection for [177 Lu]Lu-PSMA therapy, potentially leading to improved treatment outcomes in metastatic castration-resistant prostate cancer.
What to keep in mind
Most studies included were retrospective and had a moderate risk of bias.